Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.
A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.
